| SCHEDULE OF ACCOUNTS RECEIVABLE |
Accounts
receivable, net comprises the following categories (in thousands):
SCHEDULE OF ACCOUNTS RECEIVABLE
| | |
June 30, 2026 | | |
December 31, 2025 | |
| | |
| | |
| |
| Product sales | |
$ | 9,394 | | |
$ | 3,147 | |
| License revenues | |
| — | | |
| 3,000 | |
| Total accounts receivable, net | |
$ | 9,394 | | |
$ | 6,147 | |
|
| SCHEDULE OF NUMERATORS AND DENOMINATORS OF BASIC AND DILUTED NET INCOME (LOSS) PER SHARE AMOUNTS |
A
reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per share computations are as follows
(in thousands, except per share amounts):
SCHEDULE
OF NUMERATORS AND DENOMINATORS OF BASIC AND DILUTED NET INCOME (LOSS) PER SHARE AMOUNTS
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
For the three months ended June 30, | | |
For the six months ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Numerator: | |
| | | |
| | | |
| | | |
| | |
| Net (loss) income used for basic net income (loss) per share | |
$ | (20,191 | ) | |
$ | 108,833 | | |
$ | (37,266 | ) | |
$ | 96,804 | |
| Effect of dilutive securities: | |
| | | |
| | | |
| | | |
| | |
| Fair value adjustments for warrant and derivative liabilities | |
| — | | |
| 4,834 | | |
| — | | |
| (1,180 | ) |
| Numerator for dilutive net income (loss) per share - net income available for common shareholders’ after the effect of dilutive securities | |
$ | (20,191 | ) | |
$ | 113,667 | | |
$ | (37,266 | ) | |
$ | 95,624 | |
| | |
| | | |
| | | |
| | | |
| | |
| Denominator: | |
| | | |
| | | |
| | | |
| | |
| Weighted average number of common shares outstanding - basic | |
| 57,048,385 | | |
| 52,524,510 | | |
| 56,835,833 | | |
| 51,159,240 | |
| Effect of dilutive shares: | |
| | | |
| | | |
| | | |
| | |
| Shares of common stock issuable upon exercise of stock options | |
| — | | |
| 176,173 | | |
| — | | |
| 176,273 | |
| Shares of common stock underlying restricted stock | |
| — | | |
| 5,126,127 | | |
| — | | |
| 4,962,006 | |
| Shares of common stock issuable upon exercise of warrants | |
| — | | |
| 8,199,559 | | |
| — | | |
| 8,199,560 | |
| Shares of common stock issuable upon exercise of conversion feature of loan agreement | |
| — | | |
| 614,251 | | |
| — | | |
| 614,251 | |
| Dilutive potential common shares | |
| — | | |
| 14,116,110 | | |
| — | | |
| 13,952,090 | |
| Denominator for dilutive net (loss) income per share - adjusted weighted average shares used in computing net (loss) income per share - dilutive | |
| 57,048,385 | | |
| 66,640,620 | | |
| 56,835,833 | | |
| 65,111,330 | |
| | |
| | | |
| | | |
| | | |
| | |
| Earnings per share: | |
| | | |
| | | |
| | | |
| | |
| Basic (loss) income per common share | |
$ | (0.35 | ) | |
$ | 2.07 | | |
$ | (0.66 | ) | |
$ | 1.89 | |
| Dilutive (loss) income per common share | |
$ | (0.35 | ) | |
$ | 1.71 | | |
$ | (0.66 | ) | |
$ | 1.47 | |
|
| SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE |
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| | |
For the three months ended June 30, | | |
For the six months ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Shares of common stock issuable upon exercise of stock options | |
| 168,670 | | |
| — | | |
| 168,670 | | |
| — | |
| Shares of common stock underlying restricted stock | |
| 4,747,485 | | |
| — | | |
| 4,747,485 | | |
| — | |
| Shares of common stock issuable upon exercise of conversion feature of loan agreement | |
| 614,251 | | |
| — | | |
| 614,251 | | |
| — | |
| Shares of common stock issuable upon exercise of warrants | |
| 8,156,208 | | |
| 1,788,000 | | |
| 8,156,208 | | |
| 1,788,000 | |
| Total | |
| 13,686,614 | | |
| 1,788,000 | | |
| 13,686,614 | | |
| 1,788,000 | |
|